Study shows significant decline in prostate cancer diagnoses

the ONA take:

According to a new study published online in The Journal of Urology, researchers from Vanderbilt University Medical Center in Nashville, Tennessee, have found that new prostate cancer diagnoses in the United States dropped 28% in year following the United States Preventive Services Task Force (USPSTF) draft recommendation against routine prostate-specific antigen (PSA) screening for me.

For the study, researchers sought to assess the impact of the USPSTF's grade D recommendation in the year after the recommendation, which was announced in October 2011. Researchers used the National Cancer Database to identify new cancers diagnosed between January 2010 and December 2012.

Results showed that 12 months after the guidelines were published, new low-risk cancer diagnoses had decreased by 37.9%, new diagnoses of intermediate-risk disease dropped by 28.1%, and new diagnoses of high-risk prostate cancer decrease by 23.1%.

"The results raise concern that if this trend continues more men may be diagnosed at a point when their disease is advanced. Younger, healthier men with intermediate or high-risk disease would normally be candidates for aggressive local therapy and they may not be receiving a timely diagnosis under this policy," said first author Daniel Barocas, M.D., MPH, assistant professor of urological surgery and medicine.

Chemo may be preferred option for some with advanced prostate cancer
Prostate cancer diagnoses in the United States dropped 28% in year following USPSTF draft recommendation.
A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the USPSTF against routine PSA screening for men.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs